Archivio delibere
Seduta del 13/03/2012
Delibera del 13 Marzo, n. 155 [file.pdf]
Autorizzazione allo svolgimento dello studio clinico “Tak- 491 cld_307”, dal titolo: “A phase-3 randomized, doble- blind, efficacy and safety study evaluating the fixed dose combinations of tak- 491 plus chlorthalidono (40/12.5 mg and 40/25 mg) in subjects with grades 2 or 3 essential hypertension, who do not achieve target blood pressure following treatment with tak- 491 40 mg monotherapy”
SOGGETTO PROMOTORE: Quintiles spa
Autorizzazione allo svolgimento dello studio clinico “Tak- 491 cld_307”, dal titolo: “A phase-3 randomized, doble- blind, efficacy and safety study evaluating the fixed dose combinations of tak- 491 plus chlorthalidono (40/12.5 mg and 40/25 mg) in subjects with grades 2 or 3 essential hypertension, who do not achieve target blood pressure following treatment with tak- 491 40 mg monotherapy”
SOGGETTO PROMOTORE: Quintiles spa
In pubblicazione dal: 13/03/2012